Opinion|Videos|October 4, 2023
Talquetamab for Patients With Relapsed/Refractory MM
Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5